sanofi-aventis Canada is the sponsor of the UncoverT1D Early Detection Program. Revvity is the sole testing provider. The program is offered at no-cost to Canadian clinicians to identify eligible individuals in the early stages of aT1D using autoantibody testing. This program is sponsored to address unmet testing needs in the aT1D early detection space.
The UncoverT1D Early Detection Program is not intended to and should not interfere in any way with a healthcare professional’s or patient’s independent judgment and freedom of choice. Healthcare professionals and patients should always consider the full range of testing and treatment options and select those most appropriate for the individual patient.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.
